Abstract
Background The COVID-19 pandemic and March 2020 shutdown in the US reduced the volume of healthcare services, but the impact on overuse has not been investigated.
Objective To examine the change in overuse rates and volumes through 2020.
Design A retrospective cohort study using Medicare fee-for-service claims.
Setting Outpatient and inpatient claims.
Participants Patients who met the criteria for one of 10 overuse measures with a claim between January 1 2019 to December 31 2020.
Measurements Overuse volumes were reported as patients with claims meeting overuse metric criteria per 100,000 Medicare beneficiaries. Overuse rates were measured by the same overuse cohort per 100 patients meeting the denominator criteria of the metric. Rates in 2020 were compared to the same date period in 2019 using incidence rate ratios (IRRs) estimated from Poisson regressions.
Results In 2019, 302,379 patients had an overuse claim (14.72% of 2,053,792 patients in the cohort) versus 234,481 (13.79% of 1,699,807) in 2020. The overall cohort included 2,112,904 (61.0%) women and a mean (SD) age of 76.5 (8.1) years. There was a 52.3% decrease in overall cohort volume during the COVID-19 shutdown; 2,341,017 patients in 2020 versus 4,912,453 in 2019. There was a 72.57% decrease in patients with an overuse procedure between April 2019 (N = 11,794) and 2020 (N = 3,220) (IRR 0.27 (95% CI 0.25 to 0.3; p <0.001)), including spinal fusion/laminectomy, carotid endarterectomy, knee arthroscopy, hysterectomy and vertebroplasty.
Limitations This study uses claim-based measures of overuse and is limited to the first ten months of the COVID-19 pandemic.
Conclusions The shutdown period during March through May in 2020 had a drastic impact on both the overuse volume and rates for these 10 overuse metrics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was self-funded by the Lown Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of New England waived ethical approval for this work as there was no risk to patients and we did not report identifiable data. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated Figures for presentation. Updated denominators used in analysis to focus solely on overuse rates and volumes. Edits to text for clarity.
Data Availability
Medicare data was accessed after approvals and agreement with CMS. Individual hospital results will be available on https://lownhospitalsindex.org/. Other data can be accessed upon reasonable request to The Lown Institute, please contact info{at}lowninstitute.org.
